CXCR7 Targeting with Single Variable Domain Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of potent anti-CXCR7 agents is hindered by the poorly understood biology of CXCR7, including unclear mechanisms of action and low immunogenicity, making it challenging to create effective therapeutic agents that can target CXCR7 without causing toxicity or cross-reactivity.
Innovation Solution
The use of immunoglobulin single variable domains, such as VHHs, specifically directed against CXCR7 and serum albumin, to modulate and inhibit CXCR7 signaling, with compositions including these domains for therapeutic, diagnostic, or prophylactic purposes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies are used to target CXCR7, then therapeutic interference with CXCR7-mediated signaling may be achieved, but the low immunogenicity of CXCR7 and poor understanding of its biology make it difficult to generate effective agents without cross-reactivity or toxicity
Solution Approach 1:
The patent segments the antibody structure into single variable domains (VHH, dAb, or scFv) that specifically target CXCR7. These segmented antibody fragments retain the ability to bind CXCR7 with high affinity while avoiding the issues of full-length antibodies, such as Fc-mediated effects and difficulty in penetration. The segmentation allows for easier engineering and production while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent changes the structural parameters of the antibody by using single variable domains instead of full-length antibodies. This parameter change (from complete antibody structure to domain-level fragments) reduces molecular weight, improves tissue penetration, and simplifies production while maintaining specific binding to CXCR7. The parameter change also allows for easier conjugation with other therapeutic moieties.
2Adaptability or versatility
If CXCR7 is targeted with small molecular inhibitors or siRNA, then some therapeutic interference may be achieved, but the mechanism of action remains unclear and cross-reactivity with CXCR4 cannot be fully avoided
Solution Approach 1:
The patent uses single variable domain antibodies as intermediaries that specifically bind to CXCR7 and block its interaction with chemokine ligands (CXCL12/SDF-1 and CXCL11/ITAC). This intermediary approach provides a clear mechanism of action by physically preventing ligand-receptor binding, thereby blocking downstream signaling pathways involved in cell migration, proliferation, and survival. The antibody fragments serve as a precise mediator that can be engineered to target specific epitopes on CXCR7.
3Ease of manufacture
If the native conformation of active CXCR7 in cancer cells is not exactly known, then selective therapeutically effective anti-CXCR7 agents are difficult to generate, but this uncertainty still allows for exploration of potential therapeutic targets
Solution Approach 1:
The patent employs preliminary actions by using phage display technology to screen large libraries of single variable domains against CXCR7 expressed on the surface of cancer cells. This preliminary screening process identifies domains that specifically recognize CXCR7 in its native conformation on living cells, thereby overcoming the limitation of not knowing the exact active conformation. The phage display approach allows for selection of high-affinity binders that recognize the physiological state of CXCR7.
Solution Approach 2:
The patent replaces traditional mechanical/chemical methods of antibody generation (such as immunization and hybridoma technology) with phage display technology. This substitution allows for direct selection of binding domains based on their ability to recognize CXCR7 on cancer cells, bypassing the need to know the exact conformational state. The phage display system enables rapid screening and selection of specific binders through affinity-based sorting.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These immunoglobulin single variable domain-based compositions effectively bind to CXCR7, displacing CXCL12 and CXCL11, thereby modulating CXCR7-mediated signaling pathways, offering potential therapeutic and diagnostic applications for various diseases, including cancer and inflammatory disorders.
Implementation Method 1
These immunoglobulin single variable domain-based compositions effectively bind to CXCR7, displacing CXCL12 and CXCL11
Data Source
AI summary
The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.